We evaluated medical in comparison to surgical plus medical (surgical) Compared with results at 24 months, this 60-month follow-up study showed important differences in survival for patients with three-vessel disease: 75% for medical and 89% for surgical patients (p<0.02). The cumulative 5-year rate of repeat hospitalizations for cardiac reasons was less with surgical patients for either clinical presentation. For type 1, medical patients had a 56%o rate, and surgical patients had a 42% rate (p=0.004). For type 2, medical patients had a 62% rate, and surgical patients had a 43% rate (p=0.05). Overall mortality did not differ between the two treatments, and this remained true in type 1 versus type 2 patients and in those with normal versus abnormal LV function. However, regression analysis of medical and surgical groups with ejection fraction as a continuous variable showed that mortality of medical patients depended on ejection fraction (p=0.004), whereas the mortality of surgical patients did not (p=0.76), and survival in the surgical group was higher in the lowest ejection fraction tercile-73% for medical and 86% for surgical patients, p=0.03. We conclude that surgery improves survival in patients with three-vessel disease and leads to fewer subsequent hospitalizations for cardiac reasons. An impaired ejection fraction had an adverse impact on survival of medical patients but not on surgical patients, and mortality in surgical patients was improved compared with medical patients in the lowest ejection fraction tercile. (Circulation 1989;80:1176- 
a 30-month average follow-up of 288 randomized patients showing superior symptom relief but no overall survival differences between medical and surgical groups.1 Before this report, the Veterans Administration had undertaken a prospective, stratified, and randomized study of unstable angina that culminated in the enrollment of 468 patients during a 6-year period ending June 30, 1982 . The first report of end-point data at a minimum follow-up of 24 months substantially confirmed the NHLBI study conclusions on overall medical and surgical survival-a high initial crossover rate to surgery and no difference in the occurrence of nonfatal myocardial infarctions in the medical and surgical cohorts. However, significantly increased survival was shown for surgical patients who had impaired ejection fractions.2 A recent interim paper at 36 months of follow-up reported on 134 of these 468 patients with abnormal left ventricular function, which was prospectively defined as an ejection fraction less than 50% or a left ventricular end-diastolic pressure equal to or greater than 16 mm Hg. 3 The cumulative 3-year mortality for surgical patients with left ventricular dysfunction so defined was 6.1%, whereas it was 17.6% for comparable medical patients (p=0.039). This report once again addresses the outcomes of the entire 468 randomized patient cohort at a mean follow-up of 72 months (minimum of 60 months for all patients). It shows how effective medical and surgical therapies are in the longterm by providing important information on survival and cardiac events for and within each of the treatment cohorts.
Methods
Male patients less than 70 years of age admitted for chest pain were screened and offered a coronary arteriogram if they proved to have unstable angina. Their syndrome was stratified by clinical criteria into type 1 or type 2. Type 1 patients had angina pectoris for more than 2 months that had progressed symptomatically because of an increase in the frequency of episodes (doubling of the average number of attacks per day) or in its severity (doubling of the average daily dose of nitrates) or because angina appeared at rest within 8 weeks of the time when the patient was considered for entry. The qualifying symptoms had to have been present within 10 days of the date of entry. Type 1 patients also included those with angina pectoris of 2 months or less in whom pain was produced by less than ordinary activity (New York Heart Association class III) or with angina of recent onset with recurrent chest pain at rest. Electrocardiographic changes, that is, ST segment depression of 1 There was no significant difference in the distribution of these clinical and functional characteristics between medical and surgical cohorts. Specific prognostically related characteristics including age, prior myocardial infarction, diabetes, hypertension, number of major epicardial vessels involved, and ejection fraction were similarly distributed between the medical and surgical cohorts ( Table 1) .
Outcomes of Initial Hospitalization and Graft Patency
Outcome of initial hospitalization and graft patency at 1 year have been reported previously.2 No deaths occurred while the patients awaited surgery. For medical treatment, the mean and median intervals between randomization and the prerandomization start of therapy were 3.6 and 4.0 days, respectively. For surgical treatment, the mean and median intervals between randomization and operation were 9.3 and 5.0 days, respectively. Nine deaths occurred at or within 30 days of surgery, which was an operative mortality of 4.1% (4.3% for type 1; 2.1% for type 2). The average number of grafts placed was 2.7 per patient. Selective contrast arteriography at 1 Adherence to Randomization Assignment Figure 1A shows the cumulative rate of crossover of patients who failed medical therapy and received bypass surgery. Of the 237 patients originally assigned to medical therapy, 96 (43%) failed treatment and received surgical therapy by 60 months. Fifty of these patients crossed over in the first 6 months after randomization, and another 27 patients crossed over in the subsequent 12 months. Thus, more than three fourths of the patients failing medical treatment occurred within 18 months of randomization. In the first 30 days, the crossover rate was higher among patients with type 2 than among those with type 1 (19 Figure 2 ). When mortality was analyzed according to prerandomization stratification by clinical presentation, there were also no significant differences shown in survival ( Figures 3A, 3B ). The mortality for type 2 patients treated surgically was 15% compared with 23% for type 2 patients treated medically, but this difference was not statistically significant (p=0.29, Figure 3B ).
There was also no difference in 5-year mortality between the two treatment groups when the data were analyzed in terms of normal or abnormal left ventricular function or ejection fraction greater or less than 0.50 ( Table 2 ). The 60-month medical mortality for patients with ejection fraction less than 0.50 was 33% (14 of 42); the 60-month surgical mortality for patients with ejection fraction less than 0.05 was 21% (eight of 39);p=0.22. Thus, the previously reported significant 36-month survival advantage for surgical patients with ejection fractions less than 0.50 was not sustained. Because of the limitations of using left ventricular ejection fraction as a categorical variable,2 that is, with arbitrary operator cutoff points, we have continued to analyze 5-year mortality using left ventricular ejection fraction as a continuous variable (Figure 4 ). There was no dependence of mortality on left ventricular ejection fraction in the surgical group; the slope of the line relating mortality to left ventricular ejection fraction is not significantly different from zero (p=0.76). On the other hand, there is a significant (p=0.004) dependence of mortality on ejection fraction for patients treated medically. The worse the ejection fraction, the poorer was survival in the medical patients. A similar conclusion is reached when 5-year mortality is related to left ventricular function by dividing the total population into thirds throughout the entire range of ejection fraction (Table 2 ). In the lowest ejection fraction tercile, cumulative 5-year mortality for patients undergoing surgery was 14% compared with 27% for those patients treated medically (p=0.03).
When outcomes were analyzed using coronary angiographic characteristics, significant differences emerged for certain patient subgroups. Figure 5A- as a resting ejection fraction of less than 50% or a left ventricular end-diastolic pressure greater than 16 mm Hg. In that report, further classification by number of vessels diseased in these patients with left ventricular dysfunction did not show a statistically significant survival advantage for either medical or surgical treatment at 36 months. Seventy of these 134 patients had three-vessel disease, and the 36-month survival was 94% for these patients assigned to surgery and 82% for those assigned to medicine (p=0.13). Of considerable interest, analysis of survival at 5 years in this cohort with left ventricular dysfunction now shows only a trend favoring survival with surgical therapy, which no longer achieves statistical significance (p=0.09).
Our previous report2 emphasizes the strong tendency in clinical medicine to characterize left ventricular dysfunction categorically using arbitrarily assigned operator cutoff numbers to subdivide patient groups.2 Thus, when the value of <0.50 was used to define abnormal ejection fraction, there was not a consistent survival advantage to surgically assigned patients with abnormal ejection fractions at 3 and 5 years ( (Table 2) .
One question that commonly arises regarding clinical trials is just how representative randomized study subjects are in relation to the " average" patient with the same clinical problem. This issue may never be answered fully, but it is of interest to note the similarity between clinical, angiographic, and early outcome characteristics of the 468 patients randomized in this study and those of the 288 randomized in the NHLBI study (Table 5) . By protocol design, the VA study randomized only male veterans; nevertheless, in the NHLBI study' male patients were predominant, and these constituted 82% of the medical group and 86% of the surgical group. The comparability of patients surviving at 1 and 2 years in both cohorts of each study is striking. Of particular note is the greater than 90% medical survival in each study at 2 years in the medical cohorts. Before the NHLBI report, there was a considerably less optimistic prognosis for medical therapy. 16 *At entry into the study in the medical group, 52.8% of the patients were current smokers, 34 .6% had quit smoking, and 12.6% had never smoked; in the surgical group, 50% of the patients were current smokers, 42.5% had quit smoking, and 7.5% had never smoked.
S/D, systolic/diastolic; VA, Veterans Administration; NHLBI, National Heart, Lung, and Blood Institute.
lations, respectively. Nevertheless, the Oregon report indicates that in some centers and populations the outlook for surgically treated patients with unstable angina may be even better than reported here.
Therapy for acute coronary syndromes has evolved considerably in the decade since this trial was undertaken. Significant advances include use of internal mammary artery grafts, coronary angioplasty, antiplatelet agents to maintain graft patency, aspirin to abort unstable angina, and more widespread use of calcium channel blocking agents and intravenous nitrates. Thrombolysis has taken a firm foothold in early treatment of acute myocardial infarction and is being explored as a treatment for unstable angina. These interventions offer great promise for unstable angina patients. However, whether taken singly or in combination, it is not established that any of these modalities will improve the survival of patients with reduced ejection fraction or with three-vessel disease who develop unstable angina. Until further trials are forthcoming, our data indicate that coronary bypass surgery should be recommended for patients with unstable angina and reduced ejection fraction or three-vessel coronary artery disease suitable for surgical revascularization because it offers improved 5-year survival and a lower requirement for repeat cardiac hospitalization. Surgical therapy also offers the advantage of less dependence on antianginal medication. 471t (65%) *Death within 24 hours of arteriography. tThree of these 471 patients were found to have a left ventricular ejection fraction less than 0.30 after the central committee reviewed the arteriograms. These patients were observed but not included in the analyses. Thus, 468 patients constituted the study population.
